[How I Treat Non-Hodgkin's Lymphoma by Autologous Hematopoietic Stem Cell Transplantation]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2018 Mar 22

PMID 29562440

Authors

X Zhang

Affiliations

Soon will be listed here.

References

Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R . Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002; 99(12):4379-85. DOI: 10.1182/blood-2002-01-0110. View

Gutierrez-Delgado F, Maloney D, Press O, Golden J, Holmberg L, Maziarz R . Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001; 28(5):455-61. DOI: 10.1038/sj.bmt.1703179. View

Kim S, Yoon D, Kang H, Kim J, Park S, Kim H . Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012; 48(17):3223-31. DOI: 10.1016/j.ejca.2012.06.003. View

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C . Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017; 377(13):1250-1260. DOI: 10.1056/NEJMoa1701769. View

Chen Y, Lane A, Logan B, Zhu X, Akpek G, Aljurf M . Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21(6):1046-1053. PMC: 4426014. DOI: 10.1016/j.bbmt.2015.02.005. View

Shi Y, Sun Y, Liu T . [Standards for the diagnosis and treatment of malignant lymphoma (2015 version) in China]. Zhonghua Zhong Liu Za Zhi. 2015; 37(2):148-58. View

Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H . Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016; 107(12):1785-1790. PMC: 5198949. DOI: 10.1111/cas.13076. View

Zinzani P, Marchetti M, Billio A, Barosi G, Carella A, Lazzarino M . SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol. 2013; 88(3):185-92. DOI: 10.1002/ajh.23372. View

Salar A, Sierra J, Gandarillas M, Caballero M, Marin J, Lahuerta J . Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001; 27(4):405-12. DOI: 10.1038/sj.bmt.1702795. View

10.

Sweetenham J, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S . High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for.... J Clin Oncol. 2001; 19(11):2927-36. DOI: 10.1200/JCO.2001.19.11.2927. View

11.

Caballero M, Perez-Simon J, Iriondo A, Lahuerta J, Sierra J, Marin J . High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2002; 14(1):140-51. DOI: 10.1093/annonc/mdg008. View

12.

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton W, Metzner B . Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013; 31(13):1624-30. DOI: 10.1200/JCO.2012.47.1862. View

13.

Casulo C, Byrtek M, Dawson K, Zhou X, Farber C, Flowers C . Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. PMC: 4879714. DOI: 10.1200/JCO.2014.59.7534. View

14.

Maura F, Farina L, Corradini P . The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. Mediterr J Hematol Infect Dis. 2016; 8(1):e2016045. PMC: 5016019. DOI: 10.4084/MJHID.2016.045. View

15.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E . Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2012; 31(1):104-10. DOI: 10.1200/JCO.2012.43.7285. View

16.

Levine J, Harris R, Loberiza Jr F, Armitage J, Vose J, Van Besien K . A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2002; 101(7):2476-82. DOI: 10.1182/blood-2002-05-1483. View

17.

. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063. Blood. 2019; 128(3):463. DOI: 10.1182/blood-2016-06-721902. View

18.

Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H . High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011; 118(13):3504-11. DOI: 10.1182/blood-2011-01-329441. View

19.

Goy A, Sinha R, Williams M, Kalayoglu Besisik S, Drach J, Ramchandren R . Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013; 31(29):3688-95. PMC: 4879693. DOI: 10.1200/JCO.2013.49.2835. View

20.

Chow V, Rajendran J, Fisher D, Appelbaum F, Cassaday R, Martin P . A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. Am J Hematol. 2020; 95(7):775-783. DOI: 10.1002/ajh.25818. View